In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...

The U.S. Food and Drug Administration declined to approve Atara Biotherapeutics' cell therapy for a ​rare form of blood ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Incyte today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 ...

I have immersed myself in the tech world for over five years, focusing my efforts on providing readers with in-depth reviews of gadgets. Exploring the ins and outs of the latest tech has been quite a ...

Incyte INCY announced that the European Commission (EC) has approved a label expansion of Minjuvi (tafasitamab). The drug, in combination with Revlimid (lenalidomide) and rituximab, is now indicated ...

Thanks to a clinical trial for follicular lymphoma at MSK, Michael is able to spend time with family, including his granddaughter, Natalia. Retired New York City police officer Michael T. had grown ...